Human and animal studies increasingly point toward a neural pathogenesis of the metabolic syndrome, involving hypothalamic and autonomic nervous system dysfunction. We hypothesized that increased very-low-density lipoprotein − triglyceride (VLDL-TG) secretion by the liver in a rat model for dyslipidemia, that is, the obese Zucker (fa/fa) rat, is due to relative hyperactivity of sympathetic, and/or hypoactivity of parasympathetic hepatic innervation. To test the involvement of the autonomic nervous system, we surgically denervated the sympathetic or parasympathetic hepatic nerve in obese Zucker rats. Our results show that cutting the sympathetic hepatic nerve lowers VLDL-TG secretion in obese rats, finally resulting in lower plasma TG concentrations after 6 weeks. In contrast, a parasympathetic denervation results in increased plasma total cholesterol concentrations. The effect of a sympathetic or parasympathetic denervation of the liver was independent of changes in humoral factors or changes in body weight or food intake. In conclusion, a sympathetic denervation improves the lipid profile in obese Zucker rats, whereas a parasympathetic denervation increases total cholesterol levels. We believe this is a novel treatment target, which should be further investigated.
INTRODUCTION
In essence, the autonomic nervous system protects the organism from life-threatening challenges to homeostasis. Thus, it may seem paradoxical that increasing evidence in humans suggests a role for the autonomic nervous system in the development of obesity, diabetes and dyslipidemia. [1] [2] [3] However, the continuous abundance of food in our Western society may be considered unanticipated from an evolutionary perspective. Increased sympathetic and decreased parasympathetic drive correlates with several factors of the metabolic syndrome, including hypertriglyceridemia. 2 We were interested if modulation of the autonomic nervous system in the future can be a treatment for obesity and related metabolic alterations, such as dyslipidemia. In the field of hypertension the autonomic nervous system was regarded as a treatment target already in the 1930s, when the first renal denervation was carried out. Owing to major pharmacological discoveries the surgical strategy has not been used for many decades but is now again being investigated as a treatment of resistant hypertension in humans with conflicting results. 4, 5 The obese Zucker rat (fa/fa) has high TG and cholesterol plasma levels, which are already apparent shortly after weaning, due to an overproduction of very-low-density lipoprotein − triglyceride (VLDL-TG) by the liver. 6, 7 In contrast to reports of low sympathetic nerve activity to brown adipose tissue, obese Zucker rats show high levels of renal sympathetic nerve activity and elevated baseline greater splanchnic nerve activity, suggesting increased sympathetic nervous activity to the liver. 8, 9 Previous studies in lean rats provided evidence that a surgical or phenol sympathetic denervation decreases the secretion of TGs packed in VLDL particles (VLDL-TG) from the liver. 10, 11 These studies led us to believe that a sympathetic denervation of the liver may be beneficiary in reducing dyslipidemia in obese Zucker rats.
Conversely, a parasympathetic denervation might have an opposite effect as our previous study showed higher postprandial TGs after a hepatic parasympathetic denervation. 12 We tested our hypothesis in obese (fa/fa) Zucker rats by measuring plasma TG levels and hepatic VLDL-TG secretion during a timeframe of 6 weeks after a surgical sympathetic or parasympathetic denervation of the liver.
METHODS
In total, 31 obese Zucker rats (fa/fa; Charles River Germany) were included in the experiment and received a hepatic sham denervation (fa/fa sham; n = 10), hepatic sympathetic denervation (fa/fa Sx; n = 12) or a hepatic parasympathetic denervation (fa/fa Px; n = 9). For comparison, age matched lean Zucker rats with a heterozygous mutation (Fa/fa) were included and received a sham denervation (Fa/fa sham; n = 7). To achieve a hepatic sympathectomy (Sx), nerve bundles running along the hepatic artery proper were transected using microsurgical instruments. Any connective tissue attachments between the hepatic artery, bile duct and portal vein were also dissected. To achieve a hepatic parasympathectomy (Px), the common hepatic vagal branch was transected by stretching the fascia containing the common hepatic vagal branch and transecting neural tissue between the ventral vagal trunk and liver. For the fa/fa Sx rats, a successful denervation was defined as achieving a liver noradrenaline concentration after the experiment of below 1 ng g − 1 of liver tissue. We have previously validated our method for selective hepatic parasympathectomy by using retrograde viral tracing. 13 During a timeframe of 7 weeks, all rats were included in a protocol with weekly blood sampling by tail incision (weeks 0-4), a VLDL-TG secretion experiment in week 5 and a final blood sample and tissue collection (week 6) ( Figure 1a ). In addition, daily measurements of body weight, food intake and water intake were undertaken. A detailed description of the methods is provided in the Supplementary Information.
RESULTS AND DISCUSSION
As expected, obese fa/fa sham rats showed significantly higher plasma triglyceride and plasma cholesterol concentrations than lean Fa/fa sham rats at all time points ( Figure 1b) ; P o 0.01. A significant 39% decrease in plasma triglycerides was found in the obese fa/fa Sx rats compared with obese fa/fa sham (P = 0.040) and 56% compared with obese fa/fa Px (P = 0.001) rats in week 6 ( Figure 1b ; Table 1 ). Plasma total cholesterol concentrations showed no difference in obese fa/fa Sx rats compared with obese fa/fa sham rats. In contrast, we observed a significant increase of total cholesterol in obese fa/fa Px rats in week 6 compared with obese fa/fa sham (P = 0.045) and obese fa/fa Sx rats (P = 0.002) ( Figure 1d ; Table 1 ).
Obese Zucker rats are known to show increased lipoprotein lipase activity in white adipose tissue, which may partly compensate an increase in VLDL-TG secretion. 14, 15 In week 5, VLDL-TG secretion by the liver was therefore measured using tyloxapol. Tyloxapol inhibits lipoprotein lipase-mediated triglyceride hydrolysis and thus prevents the removal of circulating triglycerides by uptake in peripheral tissues. As previously shown, VLDL-TG secretion is more than twice as high in obese fa/fa sham rats compared with lean Fa/fa sham rats (Fig 1c; Po 0.001 ). Furthermore, we showed lower VLDL-TG secretion rates in the obese fa/fa Sx rats compared with obese fa/fa sham (P = 0.026) and obese fa/fa Px (P = 0.012) rats. Triglyceride accumulation curves for all groups are shown in Supplementary Figure 1 . To conclude, a sympathetic denervation lowered plasma triglycerides and VLDL-TG secretion and a parasympathetic denervation elevated total cholesterol levels.
Our results could not be attributed to changes in body weight gain and food intake. Comparison between fa/fa sham, fa/fa Sx Hepatic denervation and dyslipidemia in fa/fa rats and fa/fa Px rats revealed no significant differences in body weight during the experiment (Figure 1e ; time Po 0.001, time *denervation P = 0.334, denervation P = 0.857). Average food intake during the study was significantly increased in fa/fa sham rats compared with Fa/fa sham rats (Po 0.001), but no differences were observed between the fa/fa groups (Figure 1f ). As VLDL-TG secretion is regulated by the availability of nutrients (for example, free fatty acids and glucose) and hormones (for example, insulin and corticosterone) we measured these in the final sample (Table 1) . Obese Zucker rats are hyperinsulinemic in the face of unchanged plasma glucose concentrations and chronic hyperinsulinemia is known to increase VLDL-TG secretion. As expected, plasma insulin was significantly higher in fa/fa sham rats (7.71 ± 0.54; mean ± s.e.m.) compared with Fa/fa sham rats (1.12 ± 0.13; mean ± s.e.m.). Of note, no significant differences were observed between the fa/fa sham, fa/fa Sx and fa/fa Px rats. Furthermore, blood glucose, plasma corticosterone and plasma free fatty acids were not significantly different between fa/fa sham and Fa/fa sham rats, nor between the fa/fa denervation groups. Therefore, these humoral factors do not explain the changes observed in fa/fa Sx and Px rats and support a direct control of autonomic nerves on VLDL-TG secretion.
To our knowledge, we are the first to investigate the effects of a hepatic sympathetic denervation in Zucker rats. Surgical parasympathetic denervations in Zucker rats have been performed previously. 16, 17 Ferrari et al. 17 investigated the effect of a subdiaphragmatic vagal deafferentation, cutting all vagal afferents from the gut and liver, and leaving half of the vagal efferents intact. Contrary to our results they found decreased body weight gain, food intake, plasma insulin and triglyceride concentrations, and reduced total liver triglyceride content in subdiaphragmatic vagal deafferentation obese Zucker rats. This indicates that the effects of the subdiaphragmatic vagal deafferentation are caused by liver independent mechanisms, as we did not observe any of these effects after a selective parasympathetic denervation of the liver. The advantage of the surgical technique used in this study is that we can target the change in sympathetic activity toward a single organ. However, it does not answer which receptors are involved in the sympathetic stimulation of VLDL-TG secretion. This question is also difficult to answer with pharmacological studies, as we cannot pharmacologically target the reduction of sympathetic activity toward one single organ in a comparable physiological setting, and the off-target effects may overrule the changes induced by the target effects. On this note, in human studies a decreased clearance of triglycerides has been found after pharmacological β-blockade, probably by effects on the adipocyte. 18 Moreover, although we showed decreased VLDL-TG secretion by the liver, future experiments should investigate further the separate roles of the efferent and afferent branches of the hepatic autonomic nervous system, as a neural crosstalk between liver and adipose tissue is previously described. 19 As obese Sx rats show decreased VLDL-TG secretion we measured liver triglyceride content to investigate if a denervation leads to increased accumulation of triglycerides in the liver. Obese fa/fa sham rats showed over fourfold higher triglyceride levels in the liver compared with lean Fa/fa sham rats (P = 0.002). However, no differences were observed between the fa/fa sham, fa/fa Sx and fa/fa Px rats ( Supplementary Figure 2) . Furthermore, we investigated if fa/fa Sx rats increase their levels of fatty acid betaoxidation, leaving less substrate for VLDL-TG secretion. It is known that obese Zucker rats favor triglyceride synthesis over fatty acid oxidation and are less capable to oxidize fatty acids in the liver. 7 We observed that most long-chain acylcarnitines were decreased in obese Zucker rats, which is consistent with lower beta-oxidation when compared with lean Zucker rats ( Supplementary Figure 3) . However, fa/fa Sx rats do not display elevated levels of these acylcarnitines and therefore beta-oxidation seems unaffected in the denervated rats. Further studies are necessary to reveal the mechanism of hepatic innervation controlling the complex process of VLDL-TG maturation and secretion.
We conclude that in addition to hyperphagia and hyperinsulinemia, the autonomic nervous system is an independent determinant of VLDL-TG secretion and plasma cholesterol in obese Zucker rats. Future experiments should test if our hypothesis that obesity is correlated with an increased hepatic sympathetic drive causing increased VLDL-TG secretion, is also true in other obesity models, such as dietinduced obesity.
